This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Recently, the metal core-dielectric shell nanoparticle has demonstrated a zero backward scattering with enhanced forward scattering on a silicon substrate when surface plasmon is located in front of a solar cell.
It is said that a person, once he has drunk umm nyolokh, will return to giraffe again and again. Humr, being Mahdists, are strict abstainers [from alcohol] and a Humrawi is never drunk (sakran) on liquor or beer. But he uses this word to describe the effects which umm nyolokh has upon him. Cunnison's remarkable account of an apparently psychoactive mammal found its way from a somewhat obscure scientific paper into more mainstream literature through a conversation between W. James of the Institute of Social and Cultural Anthropology at the University of Oxford and specialist on the use of hallucinogens and intoxicants in society, and R. Rudgley, who discussed it in a book on psychoactive drugs for general readers. He speculated that a hallucinogenic compound, dimethyltryptamine (DMT), of the Giraffa (giraffe) liver might account for benevolent claims of intoxicating beverages (and potentially herbs), such as a beverage (African: umm nyolokh) used by the Arab people of Sudan like a potion. Cunnison wrote in 1958 that found it hard to believe in the literal truth of the Humr's assertion that the drink was intoxicating:
miscibility The tendency or capability of two or more substances to blend uniformly when combined (most commonly liquids, though the concept is also applicable to solids and gases), i.e. to dissolve in each other, forming a homogeneous mixture that exists in a single phase, without separation of phases, regardless of the proportions of each substance. Substances that do not mix uniformly in all proportions are said to be immiscible.
Sources: en.wikipedia.org
== See also == Animal mummy Bodies: The Exhibition Corpse decomposition Embalming Fossil Incorruptibility List of mummies List of Egyptian mummies List of DNA-tested mummies Medical cannibalism Mummia
Peter Joseph Moloney (29 June 1891, Penetanguishene, Ontario – 12 August 1989, Toronto, Ontario) was a Canadian chemist. He is known for his work on developing vaccines against diphtheria and tetanus, purifying insulin preparations for clinical use, demonstrating antibodies against insulin in humans and animals, and developing sulfated insulin preparations for the treatment of diabetics with insulin resistance. He also invented a quick-acting pH electrode and helped to develop an antiserum that was used in WW II for protection against gas gangrene.
The only war that can be fought against a superpower is a war of movement. I brought Tariq Aziz all the writings of Che Guevara and Mao Tse Tung on the arts of revolutionary war and he had them translated into Arabic. Fight a war of movement, take the uniforms off, swim among the Iraqi people and whatever their views on the regime, they will undoubtedly provide deep aquifers of support for a patriotic resistance. On 20 March 2003, a coalition including the United Kingdom and United States invaded Ba'athist Iraq. On 28 March 2003, Galloway said in an interview with Abu Dhabi TV:Iraq is fighting for all the Arabs. Why don't the Arabs do something for the Iraqis? Where are the Arab armies? ... They [Tony Blair and George Bush] have lied to the British Air Force and Navy, when they said the battle of Iraq would be very quick and easy. They attacked Iraq like wolves. They attacked civilians. They encountered resistance from Iraqi forces and Iraqi people who are defending their dignity, religion and country ... It is better for Blair and Bush to stop this crime and this catastrophe. ... The best thing British troops can do is to refuse to obey illegal orders. Labour leader Tony Blair said: "His comments were disgraceful and wrong. The National Executive will deal with it".
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.